An AllTrials project

NCT05274997: An overdue trial by Shanghai YingLi Pharmaceutical Co. Ltd.

This trial is overdue. It was due to report 1 year, 2 months ago.

Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:

  • We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
  • Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
  • Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.

Full data

Full entry on ClinicalTrials.gov NCT05274997
Title A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Results Status Overdue
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date May 1, 2022
Completion date Jan. 1, 2023
Required reporting date Jan. 1, 2024, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late 39